

## **SUPPLEMENTARY MATERIAL**

### **One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib**

Martin Bergman<sup>1</sup>, Naijun Chen<sup>2</sup>, Richard Thielen<sup>2</sup>, Patrick Zueger<sup>2</sup>


<sup>1</sup>Drexel University, College of Medicine, Philadelphia, PA, USA; <sup>2</sup>AbbVie Inc., North Chicago, IL, USA

**Corresponding Author:** Dr. Patrick Zueger

**Mailing address:** AbbVie Inc., 26525 N Riverwoods Blvd., Mettawa, Illinois, 60045, USA


**Email:** [patrick.zueger@abbvie.com](mailto:patrick.zueger@abbvie.com)

Supplementary Figure 1. Drug survival over time in all initiators



ADA, adalimumab; BARI, baricitinib; TOFA, tofacitinib; UPA, upadacitinib.

Supplementary Figure 2. Drug survival over time in TNFi-experienced patients



ADA, adalimumab; BARI, baricitinib, TNFi, tumor necrosis factor inhibitor; TOFA, tofacitinib; UPA, upadacitinib.